Clinical implications of the JAK2 V617F mutation in essential thrombocythemia

Leukemia. 2005 Oct;19(10):1847-9. doi: 10.1038/sj.leu.2403902.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Janus Kinase 2
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Polymerase Chain Reaction
  • Protein-Tyrosine Kinases / genetics*
  • Proto-Oncogene Proteins / genetics*
  • Thrombocythemia, Essential / diagnosis
  • Thrombocythemia, Essential / enzymology
  • Thrombocythemia, Essential / genetics*

Substances

  • Proto-Oncogene Proteins
  • Protein-Tyrosine Kinases
  • JAK2 protein, human
  • Janus Kinase 2